Zacks Investment Research upgraded shares of Corindus Vascular Robotics Inc (NYSEMKT:CVRS) from a hold rating to a buy rating in a research note published on Thursday morning. The firm currently has $2.00 target price on the medical equipment provider’s stock.

According to Zacks, “Corindus Vascular Robotics, Inc. is involved in designing, manufacturing and selling precision vascular robotic-assisted systems for interventional vascular procedures. The Company’s product includes CorPath 200 system a vascular robotic system which provide stent placement in percutaneous coronary intervention procedures. Corindus Vascular Robotics, Inc. is based in Waltham, Massachusetts. “

A number of other equities analysts also recently commented on CVRS. B. Riley reiterated a buy rating and set a $3.00 target price on shares of Corindus Vascular Robotics in a research note on Monday, May 15th. BidaskClub upgraded shares of Corindus Vascular Robotics from a sell rating to a hold rating in a research note on Thursday, August 10th. Cowen and Company set a $3.00 target price on shares of Corindus Vascular Robotics and gave the stock a buy rating in a research note on Wednesday, August 9th. Finally, ValuEngine upgraded shares of Corindus Vascular Robotics from a sell rating to a hold rating in a research note on Wednesday, August 23rd. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and a consensus target price of $2.67.

Shares of Corindus Vascular Robotics (CVRS) opened at 1.56 on Thursday. The stock’s market cap is $292.18 million. The stock’s 50 day moving average price is $1.69 and its 200 day moving average price is $1.42. Corindus Vascular Robotics has a one year low of $0.40 and a one year high of $2.25.

Corindus Vascular Robotics (NYSEMKT:CVRS) last issued its earnings results on Tuesday, August 8th. The medical equipment provider reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01. The firm had revenue of $2.26 million during the quarter, compared to the consensus estimate of $3.10 million. Corindus Vascular Robotics had a negative net margin of 372.63% and a negative return on equity of 94.27%. Analysts forecast that Corindus Vascular Robotics will post ($0.21) earnings per share for the current year.

WARNING: “Corindus Vascular Robotics Inc (CVRS) Upgraded to “Buy” by Zacks Investment Research” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright legislation. The original version of this piece can be read at https://www.thecerbatgem.com/2017/09/11/corindus-vascular-robotics-inc-cvrs-upgraded-to-buy-by-zacks-investment-research-2.html.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Bank of New York Mellon Corp lifted its position in Corindus Vascular Robotics by 6.3% in the first quarter. Bank of New York Mellon Corp now owns 163,012 shares of the medical equipment provider’s stock valued at $214,000 after acquiring an additional 9,684 shares during the last quarter. Rhumbline Advisers lifted its position in Corindus Vascular Robotics by 67.6% in the second quarter. Rhumbline Advisers now owns 80,868 shares of the medical equipment provider’s stock valued at $150,000 after acquiring an additional 32,608 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in Corindus Vascular Robotics by 147.8% in the second quarter. Goldman Sachs Group Inc. now owns 58,824 shares of the medical equipment provider’s stock valued at $109,000 after acquiring an additional 35,086 shares during the last quarter. California State Teachers Retirement System lifted its position in Corindus Vascular Robotics by 34.4% in the second quarter. California State Teachers Retirement System now owns 148,558 shares of the medical equipment provider’s stock valued at $276,000 after acquiring an additional 38,000 shares during the last quarter. Finally, New York State Common Retirement Fund lifted its position in Corindus Vascular Robotics by 334.6% in the second quarter. New York State Common Retirement Fund now owns 89,100 shares of the medical equipment provider’s stock valued at $166,000 after acquiring an additional 68,599 shares during the last quarter.

Corindus Vascular Robotics Company Profile

Corindus Vascular Robotics, Inc is engaged in robotic-assisted vascular interventions. The Company’s CorPath System is a medical device that brings robotic-assisted precision to radial, coronary and peripheral procedures. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries.

Get a free copy of the Zacks research report on Corindus Vascular Robotics (CVRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Corindus Vascular Robotics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corindus Vascular Robotics Inc and related stocks with our FREE daily email newsletter.